From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Moletest was initially created as a UK-based application set up in September 2010. On launch it was the world's first online remote mole screening service for the detection of non-melanoma ( e.g. Basal cell carcinoma, Squamous cell carcinoma) and melanoma skin cancers in moles. The firm developed a unique image processing technique to assess photographic images of lesions (melanocytic nevus) against known case results – providing a ‘traffic light’ based evaluation where green is a ‘normal’ lesion, amber a ‘borderline’ lesion with potentially unpredictable biological behaviour, and red a potentially ‘cancerous’ one. The company has since evolved this initial concept into a new product, nomela®. Unlike the earlier on-line system nomela® works on iOS devices and initial testing has been on the iPad. It uses a disparate selection of the earlier algorithms where each has a distinct range for melanoma. These particular algorithms have been chosen because they provide a window onto the cellular world using a close-up digital image. The rationale for nomela® is that it can safely identify, almost instantaneously, no evidence of melanoma rather than specific diagnosis of disease. The benefits arising include a 50% + reduction in referrals from Primary to Secondary Care, generating patient management efficiencies and substantial cost savings to Health Institutions and Health Insurance companies worldwide.

Moletest Limited is incorporated in Guernsey.[1] The main licensed UK company is Moletest (Scotland) Limited trading as Nomela®.

See also[edit]


  1. ^ "contact". Retrieved 27 March 2020. CS1 maint: discouraged parameter (link)

External links[edit]